The oral exposure challenge in PROTACs: What drug developers need to solve early
RegulatoryapprovedvepdegestrantVeppanuPositive
AI Analysis
Summary
The FDA approved vepdegestrant (Veppanu®) in May 2026, marking the first PROTAC drug approval and validating targeted protein degradation as a clinical modality. The article discusses the ongoing challenge of achieving adequate oral exposure in PROTAC drug development.
Outcome Details
First PROTAC drug approved by FDA
Importance:8/10
Sentiment:
0.80
PROTACtargeted protein degradationFDA approvalfirst-in-classoral drug
Read the original article
Published by Drug Discovery & Development on August 31, 2026 3:59 PM